Golden Helix

•  Website 
• Golden Helix provides several "industry-leading" software products for analyzing genome data suitable in human genetic research, pharmaceutical R&D, testing labs, and elsewhere, including:
•  SNP & Variation Suite & GenomeBrowse (analysis and visualization software for genomic and phenotype data)
•  VarSeq (a simple and fast solution for tertiary analysis) and the VSWarehouse line of tools 
• Golden Helix has worked in this field for two decades, has over 20,000 users in 400 institutions, and claims to have been cited in over 1,300 peer-reviewed publications.
• However, they are still relatively small (likely due to the niche nature of their industry space), with an estimated revenue of only $3.9 million.

IntegraGen

•  Website 
• IntegraGen is dedicated to furthering molecular research and bringing the result to clinical practices.
• Their primary line of business is the development of "biomarkers which can be used as diagnostic tools for oncology and autism spectrum disorder." To that end, the company comprises a "a network of geneticists, clinicians and biostatisticians who have mastered the most advanced genomic technologies, involving both the sequencing and genotyping of DNA and RNA."
• However, in early 2018 IntegraGen entered the Big Data SaaS market with the development of two software tools, Sirius and Mercury, which "which enable the extensive exploration of large scale genomic data to assist in the diagnosis and management of patients."
• IntegraGen reported €8.3 million in revenue in 2019, up 20% from 2018, driven in part by strong sales growth for the company's genome sequencing interpretation software, including Mercury and Sirius.

The Gene Box

•  Website 
• The Gene Box is a "pioneer in predictive analysis in lifestyle, critical illnesses and research" which partners with an array of industries, including sports & fitness, healthcare, pharmaceuticals, and others. To the latter, it offers pharmacogenomics as a solution to eliminate the hurdle of "the unpredictable nature of drug interactions on the human body."
• A 2019 story on the Mumbai-based company indicates that the company operates on two different business models: developing genetic tests for the above industries and "a SaaS-based model that works with genetic testing companies " and provides backend support.
• The Gene Box is an early-stage startup, founded in 2015, though its level of funding and sources of capital are not publicly available, but it is currently estimated to have revenue of $7.9 million.

Sophia Genetics

•  Website 
• Sophia Genetics is dedicated to leveraging big data and AI to unlock "the era of Data-Driven Medicine," particularly in what they consider "the first two pillars of Data-Driven Medicine, Genomics and Radiomics."
• The company's signature product is Sophia AI, which "leverages statistical inference, pattern recognition and machine learning to maximize the value of genomics and radiomics data." The platform is particularly promoted for its ability to accelerate the interpretation of somatic alterations in oncology, but is also useful in a wide range of genomic applications.
• Sophia is a late-stage venture, having raised over $140 million in capital over six funding rounds since its founding in 2011 and has an estimated revenue of $42 million. As of 2019, the company is used by over 900 hospitals in 77 countries. In addition, Sophia is considered a key player in the Precision Medicine Software Market.

Fabric Genomics

•  Website 
• Fabric Genomics, like Sophia, produces an "AI-driven software platform" which "enables clinical labs to uncover critical and timely genomic insights that reduce costs and save lives."
• Their signature product is Fabric AI, "a comprehensive platform for NGS analysis, interpretation and clinical reporting" which analyzes genomic data from sequencing to secondary and tertiary analysis to produce actionable reports for clinical management.
• This AI solution specifically targets oncology panels, for which it claims to be able to match cancer variants to specific clinical trials and treatments to produce "physician-ready oncology reports."
• Fabric is a late-stage venture which raised over $30 million over four funding rounds. It currently has revenue of only $13 million, but its AI solution has garnered praise from Dr. Mark Yandell, Co-Director USTAR Center for Genetic Discovery, Assoc. Director Program in Personalized Health. In addition, Fabric is considered a key player in the Precision Medicine Software Market.